Based on the existing observational studies, it remains challenging to arrive at definitive conclusions regarding the impact of pre-existing DPP-4 inhibitor (DPP-4is) therapy on COVID-19 outcomes [51]. The gene discussed is DPP4; the disease is COVID-19.